Siglec-14 Antibody (2457E) [Alexa Fluor® 647]

• Applications: Flow
• Clone: 2457E
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 647

Siglec-14 Antibody (2457E) [Alexa Fluor® 647] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line, NS0-derived human Siglec-14
  Lys18-Leu358
  Accession # Q08ET2
• Specificity: Detects human Siglec-14 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Siglecs are sialic acid specific I-type lectins that belong to the immunoglobulin superfamily. Structurally, they are transmembrane proteins with an N-terminal Ig-like V-set domain followed by a varying number of Ig-like C2-set domains (1, 2). Orthologs of Siglec-14 have not been described in mouse or rat. Mature human Siglec-14 consists of a 342 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and two Ig-like C2-set domains, a 23 aa transmembrane segment, and a 15 aa cytoplasmic tail (3). Within the first two Ig-like domains, Siglec-14 shares 99.5% aa sequence identity with Siglec-5, and 51% - 56% with Siglec-3, -6, -7, -8, and -9. Siglec-5 and -14 exhibit similar ligand preference among sialylated glycans, although Siglec-14 binds with higher avidity (3). Siglec-14 does not have the cytoplasmic ITIM sequence that mediates inhibitory signaling of most other Siglecs (2, 3). However, its transmembrane segment contains a charged arginine residue that enables association with the adaptor protein DAP12 (3, 4). Siglec-15 is the only other human Siglec identified to date that associates with DAP12 (5). Siglec-14 mRNA is primarily expressed in bone marrow, spleen, and fetal liver (3). The protein may be expressed on neutrophils, monocytes, and macrophages, as reports describing Siglec-5 on these cells employed some antibodies that also detect Siglec-14 (3, 6, 7). Siglec-5 and -14 likely function as paired receptors with similar ligand specificity and cellular expression but potentially opposing effects on cellular activation (3).

1. Varki, A. and T. Angata (2006) Glycobiology 16:1R.
2. Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
3. Angata, T. et al. (2006) FASEB J. 20:1964.
4. Turnbull, I.R. and M. Colonna (2007) Nat. Rev. Immunol. 7:155.
5. Angata, T. et al. (2007) Glycobiology 17:838.
6. Connolly, N.P. et al. (2002) Br. J. Haematol. 119:221.
7. Erickson-Miller, C.L. et al. (2003) Exp. Hematol. 31:382.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.